Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

Rgenix Announces $33M Series B Financing To Develop First-in-Class Cancer Therapeutics

by posted 2years ago 781 views
<span style="font-size: small; line-height: 20.8px;">Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP.&nbsp;</span>

In this article